Summary & Overview
HCPCS S3841: Genetic Testing for Retinoblastoma
HCPCS Level II code S3841 denotes genetic testing for retinoblastoma, a molecular diagnostic service that identifies pathogenic variants in the RB1 gene and related markers. This code is nationally relevant because genetic diagnosis informs clinical management, surveillance, family counseling, and eligibility for targeted therapies or clinical trials. Accurate coding supports appropriate coverage determinations and care coordination for patients with suspected or confirmed retinoblastoma.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the test, typical sites of service, common modifiers associated with laboratory services, and where to look for payer-specific coverage policies. The publication summarizes reimbursement and billing considerations, highlights documentation elements payers commonly request, and outlines coding relationships that affect claims processing.
This piece is intended for revenue cycle leaders, clinical geneticists, laboratory directors, and policy analysts seeking a clear national-level briefing on HCPCS Level II code S3841, its clinical purpose, and the policy and billing topics most likely to affect reimbursement and access.
Billing Code Overview
HCPCS Level II code S3841 represents genetic testing for retinoblastoma. The service involves molecular diagnostic testing to identify pathogenic variants in the RB1 gene and other genetic markers associated with retinoblastoma.
-
Service type: Genetic testing / molecular diagnostic service
-
Typical site of service: Genetic testing is typically performed in an accredited clinical laboratory; patient sample collection commonly occurs in outpatient clinics, ophthalmology practices, or hospital outpatient departments.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric patient (age range infancy to early childhood) presents to an ophthalmology clinic after clinical evaluation reveals a leukocoria and/or strabismus. Family history is notable for a first-degree relative with retinoblastoma or a history of childhood ocular tumors. The ophthalmologist orders targeted genetic testing for retinoblastoma to detect germline or somatic pathogenic variants in the RB1 gene and to characterize mosaicism. Specimen collection is performed in an outpatient clinic or genetics laboratory—typically peripheral blood for germline testing, or tumor tissue if somatic testing is indicated. The sample is processed by a molecular genetics laboratory; results guide risk assessment, surveillance planning (including periodic ocular examinations and imaging), family cascade testing, and consideration of systemic surveillance for trilateral disease. Typical sites of service include outpatient ophthalmology clinics, pediatric genetics clinics, ambulatory surgical centers (if tumor biopsy or enucleation specimens are obtained), and independent clinical molecular laboratories.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional interpretation component of the genetic test performed by a physician or qualified provider. |
TC |